Patient Characteristics
| Characteristic | Value |
|---|---|
| Patients | 14 (100%) |
| Age (y) | |
| Median | 75 (64–80) |
| ≥75 | 8 (57%) |
| ECOG performance score | |
| ≤1 | 11 (79%) |
| 2 | 3 (21%) |
| PSA at start of 225Ac-PSMA-I&T (ng/mL) | 112 (20.5–818) |
| Hemoglobin at start of 225Ac-PSMA-I&T (g/dL) | 10.3 (5.6–12.5) |
| Platelets at start of 225Ac-PSMA-I&T (g/L) | 246 (72–412) |
| ALP at start of 225Ac-PSMA-I&T (U/L) (reference range, 40−130) | 143 (67–695) |
| Site of metastases before 225Ac-PSMA-I&T | |
| Bone (any) | 13 (93%) |
| Bone (superscan pattern) | 5 (36%) |
| Lymph node | 10 (71%) |
| Visceral metastasis | 3 (21%) |
| Liver | 1 (7%) |
| Lung | 3 (21%) |
| Other organs | 1 (7%) |
| Therapy before start of 225Ac-PSMA-I&T | |
| Prostatectomy | 9 (64%) |
| Radiation therapy | 12 (86%) |
| Prostate or locoregional lymph nodes | 10 (71%) |
| Distant (nonregional lymph nodes, bone) | 6 (43%) |
| Androgen deprivation therapy | 14 (100%) |
| Abiraterone OR enzalutamide | 11 (79%) |
| Abiraterone AND enzalutamide | 4 (29%) |
| Docetaxel | 11 (79%) |
| Docetaxel AND cabazitaxel | 1 (7%) |
| 177Lu-PSMA RLT | 11 (79%) |
| 223Ra-dichloride | 2 (14%) |
ECOG = eastern cooperative oncology group.
Qualitative data are number and percentage; continuous data are median and range.